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PLASMIN  INHIBITOR  INTERACTIONS 
The Effectiveness of a2-Plasmin Inhibitor in the Presence of 
a2-Macroglobulin* 
BY PETER  C. HARPEL 
(From the  Department of  Medicine,  Division  of  Hematology, The New York Hospital-Cornell 
Medical Center,  New York 10021) 
Plasmin is  inhibited  in  vitro  by several  plasma protease  inhibitors  including 
a2-macroglobulin (1-3),  al-antitrypsin  (1,  4, 5), Ci inactivator  (6, 7),  and anti- 
thrombin-heparin cofactor  (8).  When these inhibitors  are compared in purified 
systems, a2-macroglobulin  appears  to  be  the  dominant inhibitor,  i.  2  It  is  also  an 
important inhibitor  in vivo because when plasminogen activators  are infused, 
plasmin-a2-macroglobulin complexes have been identified  (9).  Nevertheless, 
neither the role  of plasma protease inhibitors  in modulating intravascular 
proteolytic  events is  established,  nor is  it  clear  whether the entire  spectrum of 
possible  inhibitors  has been fully  defined. 
For  example, a newly  recognized  plasmin  inhibitor,  termed a2-plasmin  inhibi- 
tor,  has  been shown to  inhibit  plasmin  rapidly  (10),  thus  adding  a new aspect  to 
considerations  of  the regulation  of  plasmin activity.  In  this  communication, we 
present  experiments  which  detail  the  interactions  between a2-plasmin  inhibitor 
and as-macroglobulin  in competing for  plasmin. 
Materials and Methods 
Chemicals.  All chemicals were reagent grade. 
Plasma.  Plasma for the purification of a~-macroglobulin, a2-plasmin inhibiter, and plasmino- 
gen was obtained from fresh whole blood collected in acid-citrate-dextrose anticoagulant. 
Antisera.  Rabbit antisera produced against the following human proteins were obtained from 
Behring Diagnostics, American Hoechst Corp., Somerville, N. J.: al-antitrypsin,  Ci inactivator, 
antithrombin-heparin  cofactor,  inter-a-trypsin  inhibiter,  and chymotrypsin inhibiter. 
Plasminogen.  Plasminogen  from human  plasma was purified by insoluble-lysine affinity 
chromatography as described by Deutsch and Mertz (11),  followed by gel filtration  chromatogra- 
phy (Bio-Gel A-0.5 m, Bio-Rad Laboratories, Richmond, Calif.).  The final  preparation possessed a 
specific  activity  of  20 CTA  (Committee on Thrombolytic Agents) U/rag as assayed by a standard 
caseinolytic assay (12).  Plasminogen was labeled with I~I by the technique  of McConahey  and 
Dixon (13).  Chlorarnine-T, 0.3 ml of  a 100-~tg/ml  solution,  was added to  plasminogen, 1.3  mg in  0.5 
ml 0.15  M  phosphate buffer,  pH 7.4,  containing i  mCi of  carrier-free  1~I-sodium iodide.  After a 5- 
rain  incubation at 0°C,  0,3 ml sodium metabisulfite (100/~g/ml) was added. The unbound sodium 
iodide  was removed by gel filtration  chromatography. Labeling occurred at 0.4 ~Ci/~g plasmino- 
gen. 
Native  or  ~2~I-labeled  plasminogen  was  activated  at  25°C  by  incubation  in  a  25%  glycerol 
solution containing 0.04 M  Tris-0.016 M  lysine-0.08 M  NaCl at pH 9.0 (14) with 500 Abbot U  of 
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FIG.  1.  Interaction ofplasmin with a2-plasmin  inhibitor. Plasmin (P, 2.5 ~g), gel a, and 
a2-plasmin  inhibitor (a2-PI; 2.0 pg), gel b, were incubated together, gel c, for 2 min at 37°C. 
After incubation, these mixtures were analyzed in the absence of reduction, by electropho- 
resis on 5% SDS-acrylamide gels. The anode is toward the bottom of  the figure. The location 
of the inhibitor-plasmin complex is in~iicated (a2PI-P  Cx). 
urokinase/mg zymogen. Conversion to plasmin was documented by sodium dodecyl sulfate (SDS)  3 
gel electrophoretic analysis of reduced samples of the plasminogen-urokinase incubation mixture 
which demonstrated complete conversion of the plasminogen band to the heavy and light chain of 
plasmin. Active site titration using p-nitrophenyl p'-guanidinobenzoate hydrochloride (p-NPGB) 
was performed as  described  by Chase and Shaw (15). 
Human  a2-Macroglobulin. Human  a2-macroglobulin  was prepared as previously described 
(16).  The final  product migrated as a single  protein band aRer reduction as analyzed by SDS- 
acrylamide gel electrophoresis.  Concentrations  of a2-macroglobulin  were established by radial 
immunodiffusion (Immuno Plate,  Hyland Div.  Travenol  Laboratories,  Inc.,  Costa  Mesa, Calif.). 
Human c~2-Plasmin Inhibitor.  Human a2-plasmin inhibitor was isolated from outdated blood 
bank plasma as described by Moroi and Aoki (10). Upon cellulose acetate electrophoresis, the final 
preparation demonstrated one band with a2-mobility.  Upon SDS-gel electrophoresis, the material 
displayed a major band with an apparent M r = 67,000, consistent with that obtained by Moroi. A 
minor contaminant, Mr =  64,000, probably similar to that reported by Moroi, was also apparent 
(Fig.  1,  gel  b).  Using  specific  antibodies  and  double-diffusion  analysis,  no  detectable  a~-macroglob- 
ulin,  Ci inactivator,  a~-antitrypsin,  antithrombin-heparin  cofactor,  inter-a-trypsin  inhibitor,  or 
chymotrypsin inhibitor  were identified  in  the a2-plasmin inhibitor  preparation. 
After incubation of  az-plasmin inhibitor  with plasmin, SDS-gel electrophoretic  analysis  of  the 
unreduced mixture demonstrated a loss  of the protein bands in the a2-plasmin  inhibitor  and 
plasmin positions,  and a new higher molecular weight band was identified  (Fig.  1, gel c). The 
apparent  Mr  of  this  band  was 142,000,  consistent  with  the  formation of  a  complex between plasmin 
(Mr = 75,000)  and a2-plasmin inhibitor.  The lower  molecular  weight band in  Fig.  I,  gels  a and c, 
was a component of  the urokinase preparation added to  activate  plasminogen. 
The concentration of  functionally  active plasmin inhibitor  in the final  a2-plasmin  inhibitor 
preparation was obtained by titration  of  a known concentration of  plasmin with the inhibitor 
similar  to  the  method described  by  Mfillertz  and Clemmensen (17).  The inhibition  of  plasmin was 
found  to  be  linearly  related  to  the  volume of  inhibitor  added  to  the  incubation mixture  containing 
plasmin and the substrate H-v-valyl-leucyl-lysine-p-nitroanilide.  The concentration of active 
inhibitor  was 101 /~g/ml. 
SDS-Polyacrylamide  Gel  Electrophoresis  (5% gels).  This  was  performed  according  to  the 
method of Weber and  Osborn  (18). Samples for analysis were added to an  equal volume of a 
solution containing 10 M urea and 2% SDS,  and boiled for 5 min. 
3 Abbreviations  used in this paper: Mr, molecular weight; p-NPGB, p-nitrophenylp'-guaniXtino- 
benzoate hydrochloride; SDS,  sodium dodecyl sulfate. PETER C.  HARPEL  1035 
Studies of the Binding of l=l-Plasmin to  arMacroglabulin and  a~-Plasmin Inhibitor.  125I- 
Plasmin was prepared by the activation  of 125I-plasminogen with urokinase  as described above, 
and the activity was established by active site titration with p-NPGB. The experimental  condi- 
tions in these binding studies used physiologic concentrations of a~-macroglobulin (3.5 gM [19]) 
since it has been found that this  inhibitor  is less effective in binding  plasmin  in more dilute 
systems (unpublished observations). Since the a~-plasmin inhibitor reacts rapidly with plasmin 
even at 0°C (10), all incubation mixtures containing the inhibitors were equilibrated at 37°C before 
the addition of plasmin. Plasmin was added to a~-macroglobulin  or to mixtures of a~-macroglobu- 
lin  and  increasing  concentrations  of a~-plasmin inhibitor.  The  concentrations  of a~-plasmin 
inhibitor used in these studies (0.06-0.75 ttM) were less than those found for normal plasma (1.1 
ttM [10]). The reaction was terminated  by the addition of  the SDS-urea solution and boiling. After 
SDS-gel electrophoresis, the gels were sliced into 2-ram segments and counted in a Searle 1185 
gamma counter (Searle Analytic Inc., Des Plaines, Ill.). 
Amidolytic Assay.  Standard  plasmin curves were established  using the substrate  H-D-valyl- 
leucyl-lysine-p-nitroanilide (AB Bofors Nobel Division, Molndal, Sweden) using minor modifica- 
tions of the methods detailed  by the manufacturers.  A constant  concentration  of plasmin  was 
added to a constant  concentration  of a~-macroglobulin or to a mixture  of a2-macroglobulin and 
increasing concentrations of a~-plasmin inhibitor in the concentrations indicated in Table II. The 
final incubation volume was 1.2 ml and contained 330 gg substrate.  After a 15-rain incubation at 
37°C, 30% acetic acid (0.3 ml), was added to stop the reaction, and the abserbance was recorded at 
410 nm. Residual plasmin activity was established  from the linear plasmin standard  curves, a2- 
Macreglobulin was found not to inhibit  the amidolytic activity  of plasmin  since the residual 
activity of a mixture  of a2-macroglobulin and plasmin was similar to the activity expressed by 
plasmin alone. 
Protein.  Protein  was  measured  by the  Lowry procedure (20) with  bovine serum  albumin 
(Pentex Biochemical, Kankakee,  Ill.) as the reference standard. 
Results 
The Interaction of l~sI-Plasrnin  with a2-Macroglobulin and a2-Plasrnin  Inhibi- 
tor as Analyzed by SDS-Acrylamide Gel Electrophoresis.  To define the rela- 
tive importance of purified a2-macroglobulin and a2-plasmin inhibitor as plas- 
min inhibitors, the amount of 12SI-plasmin bound to each in incubation mixtures 
of the two was determined.  This proved feasible as preliminary studies estab- 
lished that complexes between radiolabeled plasmin and either inhibitor did not 
dissociate after electrophoresis in SDS gels. Further, the electrophoretic mobil- 
ity  of the  plasmin,  a~-macroglobulin  complex  near  the  top  of the  gel  I  was 
sufficiently different  from that  of the  plasmin,  a2-plasmin  inhibitor  complex 
(Fig. 1) to make it possible to separate these complexes in mixtures ofinhibitors 
and plasmin.  Thus,  analysis of incubation mixtures  of ~2SI-plasmin,  as-macro- 
globulin, and varying concentrations of a2-plasmin inhibitor by SDS-acrylamide 
gel electrophoresis demonstrated the quantitative contribution of each in bind- 
ing plasmin (Table I). 
In the present  studies,  concentrations of plasmin were selected which were 
well below the previously established 1 to 1 M binding capacity of a2-macroglob- 
ulin. 1 Under  these  conditions,  comparison  of the  binding  of 125I-plasmin  to 
mixtures of the inhibitors at 10 and 120 s  of incubation demonstrated that the 
reactions were complete by 10 s since no shift of radioactivity between inhibitor- 
enzyme  complexes  was  detected.  As  indicated  in  Table  I,  when  a  constant 
amount  of plasmin  (0.28  ftM)  was  added  to  a2-macroglobulin  (3.5  ftM)  and 
increasing concentrations of a~-plasmin  inhibitor  (0.06-0.75  ftM),  the  a2-plas- 
min inhibitor always bound nearly as much plasmin as it did in the absence of 1036  PLASMIN  INHIBITOR  INTERACTIONS 
TABLE  I 
The Binding of 125I-Plasmin by a2-Plasmin Inhibitor in the Presence or Absence of a2- 
Macroglobulin:  Effect of Varying the Concentration  of a2-Plasmin Inhibitor 
Concentration  a2-PI 
Incubation  mixtures  of  ~25I-plasmin  plus: 
a2M + a2-Pl*  a2-Pl~ 
~2Sl-plasmin  bound to§  ~l-plasmin  bound to 
a2-PI  a~-PI  asM 
p~/  %  %  % 
0  46.6  -  - 
0.06  41.3  5.9  0 
0.13  36.9  11.7  11.0 
0.38  12.7  29.9  32.9 
0.75  5.4  38.0  40.6 
* 5/~1 ~sSI-plasmin (0.28 ~M final concentration) was added to a mixture of 10 ~1 a~-macroglobulin 
(a2M; 3.5 ~M final concentration) and 5 ~1 buffer (0 ~M as-PI) at 37°C, or to a mixture containing 
a2M and 5  ~1 of the concentrations of a2-plasmin inhibitor (a~-PI) indicated in the table.  For 
these concentrations of a2-PI, the molar ratios relative to the concentration of asM (3.5 ~tM) are 
as follows: 0.06 ftM =  0.02; 0.13 ~M =  0.4; 0.38 ~M =  0.11; 0.75 /~M =  0.21. 
After a  10-s incubation, a  solution of SDS and urea was added to terminate the reaction. The 
mixtures were then analyzed by SDS-acrylamide gel electrophoresis,  and 2-mm gel segments 
were counted in a  gamma counter. 
5 ftl 12~I-plasmin (0.28 /~M) was incubated with buffer (0/~M ol2-PI) or with varying concentra- 
tions  of  a2-PI  as  indicated  in  the  table  and  under  the  conditions  described  above.  No  as- 
macroglobulin was included in these mixtures. 
§ Percent plasmin bound was calculated as the counts per minute associated with the 12~I-plasmin- 
a2-macroglobulin complex or with the ~2SI-plasmin-as-plasmin inhibitor complex divided by the 
sum of the cpm of these complexes plus the radioactivity of the unbound plasmin. All values are 
the mean of duplicate determinations. 
a2-macroglobulin.  This effect  was apparent in a2-plasmin inhibitor to ~-mac- 
roglobulin molar ratios as small as 0.02. 
The amount of the radiolabeled plasmin which was identified  in complexes 
with the inhibitors (46%) was in agreement  with the results of active site 
titration of  the plasmin preparation used, which demonstrated a 50% activity. 
For reasons which are  poorly understood, in  the mixture of  enzyme and inhibitor 
with the lowest concentration  of a2-plasmin inhibitor (0.06 IzM), no inhibitor- 
plasmin complex  was identified after SDS-gel electrophoresis (three experi- 
ments), although binding to  this  concentration of  inhibitor  was detectable in  the 
presence of a2-macroglobulin. 
In other experiments not shown in Table I, preincubation of  a2-macroglobulin 
(3.5 ftM) with 125I-plasmin for 2 rain at 37°C, followed by the addition of a2- 
plasmin inhibitor (0.75  ftM) for a similar incubation period, demonstrated that 
all the active plasmin remained bound to ~2-macroglobulin and none became 
associated with the a2-plasmin inhibitor.  In an experiment reversing the addi- 
tion sequence  in  which  125I-plasmin  was  added  to  ~2-plasmin  inhibitor  first 
followed  by  addition  of  a2-macroglobulin,  plasmin  was  identified  in  the  as- 
plasmin  inhibitor,  plasmin  complex,  and  none  became  associated  with  a2- PETER C.  HARPEL  1037 
macroglobulin. Thus, we conclude that after  initial  binding,  there is  no  transfer 
of  enzyme from one inhibitor  to the other. 
The Binding of Plasmin to  arMacroglobulin  in the Presence of az-Plasmin 
Inhibitor as Determined by an Amidolytic Assay.  To test for the binding of 
unlabeled, native plasmin to a2-macroglobulin in the presence of varying con- 
centrations  of  a2-plasmin  inhibitor,  a  second technique  was  utilized.  This 
method of analysis was made possible by the observation that the hydrolytic 
activity of plasmin against low molecular weight substrates was preserved after 
complex formation with a2-macroglobulin (3, 21). We first established that the 
hydrolysis of the chromogenic synthetic peptide H-v-valyl-L-leucyl-L-lysine-p- 
nitroanilide by plasmin was inhibited completely by a~-plasmin inhibitor, but 
was not inhibited when plasmin was bound to a~-macroglobulin. Furthermore, 
we established that  a2-plasmin  inhibitor caused negligible inhibition of the 
amidolytic activity of the a2-macroglobulin-plasmin complex. Therefore, when 
plasmin is added to mixtures of both inhibitors, the amount of enzyme bound to 
a2-macroglobulin can be quantitated by the preservation of amidolytic activity. 
Assays using this substrate confirmed the effectiveness of a2-plasmin inhibi- 
tor in competing with a2-macroglobulin for plasmin (Table II). Increasing con- 
centrations of a2-plasmin inhibitor in a mixture of a constant concentration of 
plasmin and a~-macroglobulin caused a reduction in the amidolytic activity of 
the incubation mixture which was proportional to the final concentration of a2- 
plasmin inhibitor added. Comparison of the plasmin activity of the incubation 
mixtures containing  a~-plasmin  inhibitor  and  plasmin  with those  mixtures 
which also included a2-macroglobulin demonstrated no significant differences. 
Thus, the a2-plasmin inhibitor competed with a2-macroglobulin as effectively 
for native plasmin as it did for the radiolabeled enzyme. 
Discussion 
Previous studies  from our  laboratory  have examined the interactions  between 
plasmin and mixtures of  purified  plasma protease inhibitors  in the concentra- 
tions  found in  plasma. In  mixtures containing a2-macroglobulin,  al-antitrypsin, 
and Ci inactivator,  the a2-macroglobulin was found to  bind most of  the plasmin 
which was added.:  In a similar  analysis,  a~-macroglobulin competed effectively 
for plasmin in the presence of  antithrombin-heparin  cofactor.  2  The addition of 
heparin, however, enabled the antithrombin-heparin  cofactor  to bind slightly 
more plasmin that did the a2-macroglobulin. Thus, in the competition among 
plasma inhibitors  for  plasmin in  the absence of  heparin, a2-macroglobulin binds 
plasmin more rapidly  than does a~-antitrypsin,  Ci inactivator,  and antithrom- 
bin-heparin cofactor. 
Moroi and Aoki (10)  have recently isolated  a plasma inhibitor  of plasmin, 
termed the a2-plasmin inhibitor,  which rapidly  formed a complex with plasmin 
and which completely inhibited  the proteolytic  and esterolytic  activity  of the 
enzyme. This inhibitor  appears to be identical  to the partially  purified,  rapidly 
acting plasmin inhibitor described by Miillertz  and Clemmensen  (17).  Both 
Miillertz  (22)  and Collen (23)  have documented that in vitro  activation  of  small 
amounts of  plasminogen in plasma results  in  the appearance of  the as-plasmin 
inhibitor-plasmin complex, which precedes the formation of the plasmin-a2- 1038  PLASMIN  INHIBITOR  INTERACTIONS 
TABLE  II 
Effect of Varying the Concentration of arPlasmin Inhibitor on the 
Binding of Plasmin to a2-Macroglobulin as Assayed Using a 
Tripeptide Substrate for Plasmin 
Incubation mixtures of plasmin plus: 
Concentration a~-PI  Plasmin activity 
a2M +  a2-PI*  ~2-PI$ 
0  0.39  0.39 
0.06  0.37  0.35 
0.13  0.29  0.31 
0.25  0.14  0.12 
0.5  0.03  0 
* 5 pl plasmin (0.4/~M final concentration of plasmin as determined by 
active site titration with p-NPGB) was added to a mixture of 5 bcl a2- 
macroglobulin (4.6/~M final concentration) and 5 ftl buffer (0 ftM as- 
PI) at 37°C, or to a mixture containing asM and 5 pl of the concentra- 
tions of a2-plasmin inhibitor indicated in the table. For these concen- 
trations of a2-PI, the molar ratios relative to the concentration of asM 
(4.6  ~M) are as follows: 0.06 /~M =  0.01; 0.13 ftM  = 0.03; 0.25 /~M = 
0.05; 0.5 ~M =  0.11. 
After a 2-rain incubation, 330  pg of the substrate (H-D-valyl-leucyl- 
lysine-p-nitroanilide) in a  1.2-ml volume was added and the mixture 
incubated an additional 15 min at 37°C. The reaction was stopped by 
the addition of 30% acetic acid (0.3 ml), and the absorbance at 410 nm 
recorded. The readings were converted to plasmin activity using a 
standard plasmin curve. All values are the mean of duplicate determi- 
nations. 
$ 5 ~l plasmin (0.4/~M) was incubated with buffer (0 ~M a2-PI) or with 
varying concentrations of as-PI as indicated in the table and under the 
conditions described above.  No  a2-macroglobulin was  included  in 
these mixtures. 
macroglobulin  complex. These observations suggest that  the  a2-macroglobulin 
may  function  as  a  plasmin  inhibitor  after  the  saturation  of the  a2-plasmin 
inhibitor. 
In  the  present  study,  we  have  examined  directly the  ability of a2-plasmin 
inhibitor to bind plasmin in the presence of a2-macroglobulin. The results of two 
different methods  designed to assess complex formation  between  plasmin  and 
these inhibitors were entirely comparable and indicated that  ~25I-plasmin bound 
as  readily  to  these  inhibitors  as  did  the  native  enzyme.  Comparison  of the 
distribution of radiolabeled plasmin  between the two inhibitors at 10 and 120  s 
of incubation showed an identical binding pattern,  indicating that the reactions 
were rapid, being completed by 10 s.  Preincubation  of plasmin  with one inhibi- 
tor followed by the addition of the other established that transfer of the enzyme 
between the inhibitors did not occur. 
The reported plasma  concentration of ~2-plasmin inhibitor (1.1  ftM [10]), and 
of a2-macroglobulin (3.5/~M [16]), represents a  molar ratio of 0.3. In our binding 
studies,  a2-plasmin inhibitor to a2-macroglobulin molar ratios from 0.01  to 0.21 PETER C.  HARPEL  1039 
have been examined. Over this range of a2-plasmin inhibitor concentrations, 
approximately  as  much  plasmin  was  bound  to  the  a2-plasmin  inhibitor  in 
mixtures which  contained  a2-macroglobulin as  in  those which  did  not.  This 
indicates that when both inhibitors simultaneously compete for plasmin, the a2- 
plasmin  inhibitor  binds  the  enzyme  much  more  rapidly  than  does  the  a2- 
macroglobulin. These data strengthen the concept that the a2-plasmin inhibitor 
may represent the primary plasmin inhibitor in the circulating blood. 
Summary 
a2-Plasmin inhibitor and  a2-macroglobulin were allowed to compete for the 
protease plasmin. The binding of the enzyme to these inhibitors was assessed by 
two different but comparable methods. The interactions were completed in 10 s 
of incubation, and transfer of plasmin from one inhibitor to the other did not 
occur. Almost as much plasmin was bound to a2-plasmin inhibitor in mixtures 
containing a  large molar excess of a2-macroglobulin relative to plasmin or a2- 
plasmin inhibitor, as was bound in mixtures not containing a2-macroglobulin. 
These studies demonstrate directly the effectiveness of a2-plasmin inhibitor in 
binding and inhibiting plasmin in the presence of a2-macroglobulin, and suggest 
that the a2-plasmin inhibitor may be the major circulating plasmin inhibitor. 
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